Recital 70, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

As illustrated in Table 3 below, AniCura accounts for between [20-30]% and [20-

30]% of the market in Sweden, Denmark and the Netherlands, and when AniCura's market shares are considered together with VetFamily's, these increase to [40-50]% in Sweden, [40-50]% in Denmark and [30-40]% in the Netherlands.

Table 3: Share estimates for AniCura’s and VetFamily's (projected) provision of veterinary services in the affected markets (2017, based on turnover) AniCura market share71 VetFamily market share AniCura & VetFamily combined market share Other clinics (not belonging to AniCura or VetFamily) Sweden [20-30]% [20-30]% [40-50]% [50-60]% Denmark [20-30]% [20-30]% [40-50]% [50-60]% Netherlands72 [20-30]% [10-20]% [30-40]% [60-70]% Germany [0-5]% [0-5]% [5-10]% [90-100]% Austria [0-5]% [0-5]% [0-5]% [90-100]% Italy [0-5]% [0-5]% [0-5]% [90-100]% France [0-5]% [0-5]% [0-5]% [90-100]% Spain [0-5]% [0-5]% [0-5]% [90-100]% Source: Parties' response to RFI 12